Patients with advanced non-small-cell lung cancer (NSCLC) are benefited from First-line nivolumab plus ipilimumab. This trial was basically on the improvement of this technique. Not just improvement, but this was a test that can help to extend the survival of these patients. In this trial, an additional dose of chemotherapy was given to these patients in a limited form. All this was done to enhance the clinical effect.
From Aug 24, 2017, and Jan 30, 2019, approx 1150 patients enrolled for the trial, and 719 randomly assigned to the 2nd cycle of chemotherapy. Even some of them went for four cycles alone. All this was done with nivolumab plus ipilimumab. When analyzed, it was seen that the survival duration of the experimental patients was more in most of the cases than that of the control. Many other effects were seen, as mentioned in the article, with time and certain doses.
To summarize, one can easily say, based on the study and the data observed, that nivolumab plus ipilimumab, when combined with two cycles of chemotherapy, gives a long-lasting and better result. Not just in the phase of treatments, but it gives improved results in the phase of survival.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/fulltext
